Tivozanib Hydrochloride
Grundinformationen
- CAS
682745-41-1- Standard-SMILES
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC.Cl.O- InChIKey
RQXMKRRBJITKRN-UHFFFAOYSA-N- Summenformel
- C22H22Cl2N4O6
- Durchschnittliche Molmasse
- 509,3 g/mol
- Monoisotopische Masse
- 508,0916398
Überblick
Tivozanib Hydrochloride is the hydrochloride salt of tivozanib, an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.
Namen und Bezeichner
- Bevorzugter Name
- Tivozanib Hydrochloride
- IUPAC
- 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea;hydrate;hydrochloride
- Englischer Name
- Tivozanib
- Summenformel
- C22H22Cl2N4O6
- Molmasse
- 509.34
Namen und Synonyme
TIVOZANIB HYDROCHLORIDE682745-41-1Tivozanib hydrochloride hydrateTivozanib HCl hydrateTivozanib hydrochloride monohydrateUNII-8A9H4VK35Z8A9H4VK35ZfotivdaTivozanib monohydrochloride monohydrateRefChem:58430UREA, N-(2-CHLORO-4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(5-METHYL-3-ISOXAZOLYL)-, HYDROCHLORIDE, HYDRATE (1:1:1)Tivozanib (hydrochloride hydrate)
Weitere Namen anzeigen
Tivozanib HCl API1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)ureaN-[2-Chloro-4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(5-methyl-3-isoxazolyl)-urea monohydrochloride monohydrate
Tivozanib hydrochloride [USAN](TIVOZANIB HYDROCHLORIDE HYDRATETivozanib hydrochloride (USAN)1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea;hydrate;hydrochlorideASP-4130Fotivda (TN)Clorhidrato de tivozanibCloridrato de Tivozanibe
Datenbank-Bezeichner
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 109 Ų
- H-Brücken-Donoren
- 4
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 6
- Schwere Atome
- 34
- Formalladung
- 0
- Komplexität
- 631
Experimentelle und physikochemische Eigenschaften
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
Physikochemische Eigenschaften
- storage temp.
- 4 °C, · 4°C, away from moisture and light
- Löslichkeit
- 250 mg/mL · DMSO : 250 mg/mL (490.83 mM; Need ultrasonic)
- Aggregatzustand
- Solid
- Farbe
- White to off-white
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Tivozanib hydrochloride
Ambiguous-DILI-concern
4
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Chemie und Industrie
Anwendungen
VerwendenTivozanib also known as AV-951 is an orally bioavailable potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively.
Anbieter
Wird geladen…
Öffentliche Anfragen
Wird geladen…
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…